Real-world data showed that Bruton tyrosine kinase inhibitors were a reasonable therapeutic option for patients with chronic lymphocytic leukemia and severe renal impairment, including for older adults and those on dialysis.
We’re sorry, but an unexpected error has occurred.
Please refresh your browser and try again. If this error persists, please contact ITSupport@wyanokegroup.com for assistance.
Would you like to receive email reminders to complete your saved activities from Healio CME?
Activity saved! You'll receive reminders to complete your saved activities from Healio CME.
